NasdaqGS:ROIVBiotechs
Did Roivant’s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy?
In May 2026, Roivant Sciences reported fourth-quarter sales of US$2.52 million with net income of US$302.99 million, alongside a full-year net loss of US$299.77 million on US$8.26 million in sales.
On the same day, the company filed a nearly US$981.62 million shelf registration for up to 34,796,916 common shares tied to employee stock plans, highlighting both recent profitability at the quarter level and potential future dilution.
Next, we’ll examine how the sharp quarterly swing to...